Total revenue growth of 17%; Software revenue growth of 16%; Services revenue growth of 19%;
Diluted Earnings Per Share (EPS) growth of 11%;
Board of Directors announces quarterly dividend of $0.06 per share
Understanding Interindividual Variability in the Drug Interaction of a Highly Extracted CYP1A2 Substrate Tizanidine: Application of a Permeability-Limited Multicompartment Liver Model in a Population Based Physiologically Based Pharmacokinetic Framework
Tizanidine, a centrally acting skeletal muscle relaxant, is predominantly metabolized by CYP1A2 and undergoes extensive hepatic first-pass metabolism after oral administration.
First in Human (FIH) PBPK predictions
An overview of what PBPK is will be provided so that everyone starts from the same level.
Simulations Plus Hosts 2nd Annual Pharmacometrics Workshop
Record-setting attendance for the global pharmacometrics community
Using PBPK modeling to assess the impact of diseases on oral drug absorption: case study in HIV-infected patients
Randomized clinical trial is the most effective way to determine whether a cause-and-effect relationship exists between an intervention and a predefined clinical outcome.
Simulation of febuxostat pharmacokinetics in healthy subjects and patients with impaired kidney function using physiologically based pharmacokinetic modeling
Febuxostat is recommended by the American College of Rheumatology Gout Management Guidelines as a first-line therapy for lowering the level of urate in patients with gout.
Data required to build a fit-for-purpose PBPK model: How much is necessary?
PBPK/PBBM model development can be initiated at any stage of product development
Simulations Plus Collaborates with Multinational Pharmaceutical Company to Provide Modeling & Simulation Support for COVID-19 Treatment
Simulations Plus' Cognigen division worked with a major pharmaceutical company to implement modeling and simulation activities to support the development of a candidate COVID-19 therapy.
Simulations Plus Sets Date for Third Quarter Fiscal Year 2022 Earnings Release and Conference Call
Conference call to be on Wednesday, July 6, 2022, at 5:00 PM ET
Impact of Composition and Morphology of Ketoconazole-Loaded Solid Lipid Nanoparticles on Intestinal Permeation and Gastroplus-Based Prediction Studies
Ketoconazole (KTZ) is a potential oral antifungal agent to control systemic and local infections.
From traditional to data-driven medicinal chemistry: A case study
Artificial intelligence (AI) and data science are beginning to impact drug discovery.
Machine Learning guided early drug discovery of small molecules
Machine learning (ML) approaches have been widely adopted within the early stages of the drug discovery process, particularly within the context of small-molecule drug...
An update on the comparison of lixivaptan’s liver safety profile
An update from Dr. Paul B. Watkins on the comparison of lixivaptan’s liver safety profile
DILIsym Software Publication Outlines Impact on the CGRP Field for Migraine
DILIsym application contributes to approval of new drugs for migraine treatment
Predictive Dissolution Modeling with Clinically Relevant Specifications
The role of biopharmaceutics risk assessment
June 2022 GastroPlus Newsletter
Hello again GastroPlus scientists, Simulations Plus is a great place to work.
Absence of association between abatacept exposure levels and initial infection in patients with RA: a post hoc analysis of the randomized, placebo-controlled AVERT-2 study
Infections are the most commonly reported AEs in patients with RA treated with immunosuppressive therapies, and
Using GastroPlus to teach complex biopharmaceutical concepts
This report showcases the use of the software GastroPlus in an undergraduate-level pharmacy course.